Mundipharma Company Profile

12:55 EST 18th November 2017 | BioPortfolio

The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. The Mundipharma network has a presence in 51 countries with more than 7,800 employees across the world. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of pain management, oncology, respiratory and inflammatory conditions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers important treatments to meet the most pressing needs of patients, healthcare professionals and health systems worldwide.

News Articles [36 Associated News Articles listed on BioPortfolio]

Mundipharma: A boutique organization with an entrepreneurial spirit

Mundipharma is a network of organisations across Europe, and internationally, with a therapeutic focus on pain management, addiction and respiratory therapies. Allen Downs discusses Mundipharma’s as...

Mundipharma identifies barriers to market access, offers solutions

A research paper sponsored by UK-based Mundipharma International together with the University of Cambridge…

Bile duct cancer candidate bought by Mundipharma in deal worth up to $250 million

Cambridge, UK-based Mundipharma has bought the global rights to CAP7.1, a novel prodrug of the chemotherapeutic…

Mundipharma to distribute J&J diabetes drugs in Europe

European pharma group Mundipharma has struck a deal with Janssen for two primary care diabetes drugs, Invokana and Vokanamet, in selected European countries. The deal will see Mundipharma distribute ...

Mundipharma to market diabetes drugs in EU, Switzerland

Mundipharma will promote, distribute and sell type 2 diabetes drugs Invokana and Vokanamet in the European Economic Area coun -More- 

Mundipharma buys rights to CellAct cancer drug

European independent pharma network Mundipharma has bought worldwide rights to develop, market and manufacture cancer drug CAP7.1 from Germany’s CellAct. A network of independent associated compa...

Mundipharma EDO initiates Phase I/II oncology trial of tinostamustine in US

Switzerland-based Mundipharma EDO has initiated a Phase I/II clinical trial of tinostamustine (EDO-S101) to treat patients with advanced solid tumours in the US.

Mundipharma gains rights to smart chemotherapy CAP7.1 from CellAct

Mundipharma International Corp. Ltd. licensed global rights to CellAct Pharma GMBH’s etoposide prodrug CAP7.1, which is in Phase II trials for biliary tract cancer.

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [4 Associated Companies listed on BioPortfolio]


The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. The Mundipharma n...

Mundipharma International Ltd

The Mundipharma International Group of Companies are privately owned associated companies and joint ventures covering the world’s pharmaceutical markets. The Group is particularly strong in analgesi...

Mundipharma International Limited


Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. Novelos is seeking to bui...

More Information about "Mundipharma" on BioPortfolio

We have published hundreds of Mundipharma news stories on BioPortfolio along with dozens of Mundipharma Clinical Trials and PubMed Articles about Mundipharma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mundipharma Companies in our database. You can also find out about relevant Mundipharma Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record